2022 年第 10 期 第 17 卷

人表皮生长因子受体2阳性乳腺癌脑转移治疗的研究进展

Research progress on the treatment of human epidermal growth factor-2 positive breast cancer with brain metastasis

作者：李治荣1田武国2

英文作者：Li Zhirong1 Tian Wuguo2

单位：1重庆医科大学附属大学城医院消化中心，重庆401331；2陆军军医大学大坪医院乳腺甲状腺外科，重庆400042

英文单位：1Department of Digestive Center University-Town Hospital of Chongqing Medical University Chongqing 401331 China; 2Department of Breast and Thyroid Surgery Daping Hospital Army Medical University Chongqing 400042 China

关键词：人表皮生长因子受体2；乳腺癌脑转移；局部治疗；全身治疗

英文关键词：Humanepidermalgrowthfactor-2;Breastcancerwithbrainmetastases;Localtherapy;Systemictherapy

• 摘要：

• 人表皮生长因子受体2（HER-2）过表达是乳腺癌患者发生脑转移的重要危险因素之一。以手术和放疗为主的局部治疗提高了脑转移的局部控制效果，抗HER-2药物的使用也一定程度上改善了HER-2阳性乳腺癌脑转移（BCBM）患者的预后。随着几种新药的开发、给药方式的进步和联合治疗的出现使药物更容易进入病灶，为HER-2阳性BCBM患者提供了新的治疗方式并提高了生存获益。本文将介绍HER-2阳性BCBM在局部治疗和全身系统性治疗领域的新进展，为该类患者提供治疗参考。

• Human epidermal growth factor-2 (HER-2) overexpression is an important risk factor for brain metastases in patients with breast cancer. Local treatment, mainly surgery and radiotherapy, improves the local control effect of brain metastases, and the use of anti-HER-2 drugs also improves the prognosis of HER-2 positive breast cancer with brain metastases（BCBM） to a certain extent. With the development of several new drugs, advances in administration, and the advent of combination therapy to allow easier access to lesions, patients with HER-2 positive BCBM have been offered new treatment modalities and improved survival benefits. This article introduces the research Results of current and new treatment modalities for HER-2 positive BCBM patients, so as to provide treatment reference for the patients.